000 02514cam a2200301 4500500
005 20250112030525.0
041 _afre
042 _adc
100 1 0 _aEl Khayari, Maryame
_eauthor
700 1 0 _a Maroute, Chaimae
_eauthor
700 1 0 _a Machraoui, Lamyae
_eauthor
700 1 0 _a Benajah, Dafrlah
_eauthor
700 1 0 _a El Abkari, Mohamed
_eauthor
700 1 0 _a Ibrahimi, Adil
_eauthor
700 1 0 _a Amara, Bouchra
_eauthor
700 1 0 _a El Maghraoui, Imane
_eauthor
700 1 0 _a Zarrouq, Btissam
_eauthor
700 1 0 _a Halim, Karima
_eauthor
700 1 0 _a Ragala, Mohammed Elamine
_eauthor
700 1 0 _a Bennani, Bahia
_eauthor
700 1 0 _a Lahmidani, Nada
_eauthor
245 0 0 _aPeptic ulcer disease: The role of tobacco and Helicobacter pylori infection and tobacco–Helicobacter pylori interaction
260 _c2022.
500 _a89
520 _aPeptic ulcer disease (PUD) is a common condition worldwide with significant morbidity. Mortality is specifically related to complications of the disease, especially bleeding, and the patient’s comorbidities. PUD is a multifactorial disease linked, among other things, to Helicobacter pylori (HP) infection, which plays a fundamental role in the development of peptic ulcer disease and whose eradication leads to better ulcer healing and fewer recurrences of the disease. [3] Smoking is a major independent risk factor for the development of peptic ulcer disease (PUD), as well as for the occurrence of stenotic, bleeding, and perforative complications. It is estimated that 60–65% of complicated PUDs occur in patients who smoke. Smoking is also associated with delayed PUD healing, a risk of ulcer recurrence, and HP eradication failure, even after controlling for socio-demographic factors considered to be main confounders [4]. These data underline the importance of treating tobacco dependence in ulcer patients, as well as the importance of understanding the interaction between tobacco and HP. This investigation therefore constitutes a valuable resource on the pathology in relation to the effect of tobacco and HP, which can be used to improve the diagnostic and therapeutic management of PUD, using multiple gastroenterological, microbiological, and molecular approaches, as well as behavioral mechanisms.
786 0 _nCahiers Santé Médecine Thérapeutique | 31 | 5-6 | 2022-09-01 | p. 273-278 | 2780-8858
856 4 1 _uhttps://shs.cairn.info/journal-cahiers-sante-medecine-therapeutique-2022-5-6-page-273?lang=en
999 _c152496
_d152496